Compare Humana Inc (HUM) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Nvidia Corp — how do they compare? Humana Inc trades at $431.03 (market cap $46.49B), while Nvidia Corp trades at $229.28 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 119.8× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Nvidia Corp for 115 Days on average.
| HUM | NVDA | |
|---|---|---|
Market Cap | $46.49B | $5.57T |
Volume | 2,567,704 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $409.85 | $239.27 |
52-Week Low | $163.67 | $165.17 |
Typical Hold Time | 51 Days | 115 Days |
Enterprise Value | $53.84B | $5.54T |
Dividend Yield | 0.91% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 2.37% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $457.05 implying 18% upside. Revenue growth is robust, reaching $129.7 billion in 2025, though net income margin has compressed to 0.88%. Recent news includes a Barclays upgrade to a $515 target and upcoming Q3 earnings on November 6, 2026.
The stock offers potential from strong revenue expansion and positive analyst sentiment, but faces risks from margin pressure and regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes. The outlook hinges on earnings performance and Medicare Advantage plan changes affecting membership.
NVIDIA (NVDA) trades at $230.48, down 2.9% on the day, with strong technical support at $228 and resistance at $235. The company demonstrates exceptional fundamental strength with 2025 revenue of $130.5 billion and net income of $72.9 billion, representing a 55.8% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 forecast.
NVIDIA maintains a dominant position in AI chip markets with accelerating revenue growth projected to reach $303 billion in 2026. While valuation multiples appear elevated (P/E 29.1, P/S 18.6), the consensus price target of $339.17 suggests 47% upside potential. Key risks include increased competition and potential peak AI infrastructure spending, but strong institutional support and positive analyst sentiment (76% buy ratings) support the bullish outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
